Key Takeaways:
NRx Pharmaceuticals Inc. (Nasdaq: NRXP) received a positive Discipline Review Letter from the US Food and Drug Administration’s Office of Generic Drugs for its preservative-free ketamine intravenous formulation, NRX-100. The agency letter requested only “minor” administrative changes, moving the drug closer to a potential approval targeted for summer 2026.
"Every 11 minutes an American dies from suicide. Every day we lose 20 or more Veterans and Soldiers, along with countless first responders," Dr. Jonathan C. Javitt, CEO and Chairman of NRx, said in a statement. "We are committed to working with FDA to bring lifesaving treatments to patients who need them.”
The quality review letter follows a favorable bioequivalence determination from the FDA on March 17 and covers the areas of Drug Substance, Drug Product, Manufacturing, and Microbiology. In a subsequent meeting, FDA leadership acknowledged the national priority to expedite ketamine approval, a goal supported by a recent Executive Order, and expressed support for addressing remaining application aspects within the current review cycle.
This progress significantly de-risks the regulatory path for NRX-100, which is being developed for suicidal depression, chronic pain, and PTSD. NRx’s formulation is notable for not containing Benzethonium Chloride, a preservative no longer permitted in new drugs. A potential approval could address documented supply shortages of ketamine for clinical use.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on central nervous system disorders. Beyond the intravenous ketamine ANDA, the company has initiated a New Drug Application for NRX-100 and is also developing NRX-101, an oral combination of D-cycloserine and lurasidone. NRX-101 has received Breakthrough Therapy Designation for treating suicidal bipolar depression.
The positive FDA feedback suggests a clearer path to market for NRX-100, which holds Fast Track Designation for treating suicidal ideation. Investors will be watching for the final approval decision, which the company anticipates in summer 2026.
This article is for informational purposes only and does not constitute investment advice.
